Equities

Traws Pharma Inc

Traws Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4368
  • Today's Change-0.010 / -2.28%
  • Shares traded23.51k
  • 1 Year change-57.39%
  • Beta1.3773
Data delayed at least 15 minutes, as of Jul 24 2024 19:24 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

  • Revenue in USD (TTM)226.00k
  • Net income in USD-18.16m
  • Incorporated1998
  • Employees16.00
  • Location
    Traws Pharma Inc12 Penns TrailNEWTOWN 18940United StatesUSA
  • Phone+1 (267) 759-3680
  • Fax+1 (267) 759-3681
  • Websitehttps://www.onconova.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Senti Biosciences Inc1.28m-86.11m10.75m48.00--0.1915--8.43-19.29-14.420.284712.270.0097--2.9426,562.50-65.33---71.42-------6,753.80------0.0018---40.25---67.94------
Enzon Pharmaceuticals Inc0.00221.00k10.76m0.0048.663.27----0.0030.0030.000.6240.00------3.21-0.86543.24-0.8851-------159.43----0.00---100.00--106.71-55.86----
Eterna Therapeutics Inc115.00k-22.92m10.81m8.00------94.02-4.25-4.250.0214-0.63070.0036--0.230514,375.00-70.71-169.05-88.77-223.00-114.78---19,912.17-682.61---15.551.64-----68.8911.84---58.86--
Dominari Holdings Inc3.41m-24.56m10.86m26.00--0.2278--3.19-4.64-4.640.63058.030.0539--0.8023131,000.00-38.88-26.82-39.93-27.45-----721.11-3,353.52----0.00----135.7512.72--63.99--
Calidi Biotherapeutics Inc0.00-29.98m10.91m41.00---------6.76-6.760.00-4.080.00----0.00-382.78-----------------27.45-----100.00---14.90------
Inhibikase Therapeutics Inc195.98k-19.20m11.26m8.00--1.49--57.44-3.38-3.380.0341.050.01--6.0824,497.50-97.88-66.49-118.76-85.55-----9,797.30-1,139.14----0.00--111.03-42.21-5.40------
Monopar Therapeutics Inc0.00-7.61m11.27m10.00--1.50-----0.5289-0.52890.000.42770.00----0.00-73.36-54.07-92.67-60.60------------0.00------20.10------
Traws Pharma Inc226.00k-18.16m11.31m16.00--1.57--50.04-0.8641-0.86410.01080.28530.0085--12.9114,125.00-68.21-63.43-104.99-85.72-----8,033.63-3,257.92----0.00--0.00-28.720.0844------
Kazia Therapeutics Ltd (ADR)14.92k-13.54m11.32m12.00--1.09--758.75-0.821-0.8210.00080.34950.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Cardio Diagnostics Holdings Inc33.00k-11.51m11.41m7.00--3.58--345.71-0.8257-0.82570.00210.14040.0051----4,714.29-178.70---325.81-------34,872.12-----4.840.0715--1,696.84---79.72------
Vaccinex Inc124.00k-19.19m11.53m37.00--8.13--93.01-46.02-46.020.16851.680.0202--0.08943,351.35-312.93-262.29-731.45-------15,472.58-4,257.17---55.900.03--107.27-4.67-2.20---22.20--
BioRestorative Therapies Inc149.50k-6.96m11.58m11.00--0.799--77.44-1.49-1.490.03022.140.0093--5.8613,590.91-43.44-192.11-49.49-329.32-----4,653.34-19,116.15----0.00--21.705.6143.67--67.77--
Imunon Inc0.00-18.85m11.75m33.00--1.38-----2.02-2.020.000.90410.00----0.00-66.82-50.18-91.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Check Cap Ltd0.00-17.57m11.82m85.00--0.4989-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Data as of Jul 24 2024. Currency figures normalised to Traws Pharma Inc's reporting currency: US Dollar USD

Institutional shareholders

10.63%Per cent of shares held by top holders
HolderShares% Held
OrbiMed Advisors LLCas of 01 Apr 20241.05m4.13%
The Vanguard Group, Inc.as of 31 Mar 2024702.07k2.78%
Renaissance Technologies LLCas of 31 Mar 2024268.19k1.06%
BlackRock Fund Advisorsas of 31 Mar 2024248.88k0.98%
Geode Capital Management LLCas of 31 Mar 2024192.86k0.76%
Two Sigma Advisers LPas of 31 Mar 202473.07k0.29%
SSgA Funds Management, Inc.as of 31 Mar 202452.79k0.21%
Two Sigma Investments LPas of 31 Mar 202437.99k0.15%
Citadel Securities LLCas of 31 Mar 202436.82k0.15%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202430.78k0.12%
More ▼
Data from 31 Mar 2024 - 01 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.